An observational study in Type2 Diabetes, sponsored by Perspectum. Recruiting at 12 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-05.
Sponsored by Perspectum · Observational
Prospective, observational cohort study to cross-sectionally assess the health of multiple organs, using multiparametric abdominal magnetic resonance imaging (MRI) scan, and understand if resulting MRI metrics can predict future clinical events over a period of 5 years, in adult patients with type 2 diabetes lacking history of cardiovascular disease.
This will be a multi-site study adopting a prospective, observational cohort study design. There will be no intervention to the standard of care. Study participants will be enrolled in this study for a total of 5 years, with only 1 month of active participation. Participants will be required to attend a screening visit and 2 study visits. The screening visit will involve a medical review and receiving informed consent based on the participant information leaflet already communicated to the patient, pre-screening. The first study visit- baseline (visit 1) - will involve anthropometric measurements and taking a blood and urine sample in order to perform standard of care measurements for type 2 diabetes at baseline and relevant circulating biomarkers. The second study visit will involve having a multi-organ, multiparametric MRI scan. Both visits will be within 28 days of the screening visit and carried out at local study sites.
MRI metrics of organ health, clinical outcome measurements, blood samples and urine samples will be collected to assess the natural history of diabetes disease progression. Participants will be asked to give consent for access to their medical records held at NHS England and, if available, at their local GP surgery or hospital. Medical records access will include Hospital admissions (Hospital Episode Statistics), and mortality data collected by the Office for National Statistics and provided by NHS England to meet the primary objective. This data will be collected at 1, 3 and 5 years after baseline assessment.
10,371 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,406 are open to participants now.
This study's planned enrollment of 1,000 is above the median of 300 across 1,741 observational studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Perspectum is the lead sponsor of 27 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adult participants, aged 18 years of age and over with type 2 diabetes lacking history of cardiovascular disease. Recruitment will be carried out from patients identified following diabetes or diabetic retinopathy diagnoses or via self-referral.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
In 12 months prior to consent, evidence of existing cardiovascular event defined as at least one of:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with type 2 diabetes, especially individuals who have been diagnosed in the last three years
Other: MRI
MRI is not part of Pathway for patient with type two diabetes.
Baseline liver MR metrics on incidence rate of 5-point MACE (CV death, non-fatal stroke, myocardial infarction, heart failure, hospitalisation for CV causes) in people with type 2 diabetes, without history of CV.
The impact of liver fibroinflammation (cT1 from multi-organ MRI) on cardiovascular clinical outcomes in a patient population with type 2 diabetes without history of cardiovascular disease.
Time frame: 3 year from baseline
The effect of baseline liver MR metrics (cT1 and fat) on the incidence rate of composite severe renal disease events (renal replacement therapy, renal death).
The impact of liver fibroinflammation (cT1 from multi-organ MRI) on other diabetes-related outcomes
Time frame: 1 year from baseline
The effect of baseline liver MR metrics (cT1 and fat) on the incidence rate of composite severe renal disease events (renal replacement therapy, renal death).
The impact of liver fibroinflammation (cT1 from multi-organ MRI) on other diabetes-related outcomes
Time frame: 3 years from baseline
The effect of baseline liver MR metrics (cT1 and fat) on the incidence rate of composite severe renal disease events (renal replacement therapy, renal death).
The impact of liver fibroinflammation (cT1 from multi-organ MRI) on other diabetes-related outcomes
Time frame: 5 years from baseline
The effect of baseline liver MR metrics (cT1 and fat) on the incidence rate of composite mild renal disease events (incident CKD, change in stage of CKD)
The impact of liver fibroinflammation (cT1 from multi-organ MRI) on other diabetes-related outcomes
Time frame: 1 year from baseline
The effect of baseline liver MR metrics (cT1 and fat) on the incidence rate of composite mild renal disease events (incident CKD, change in stage of CKD)
The impact of liver fibroinflammation (cT1 from multi-organ MRI) on other diabetes-related outcomes
Time frame: 3 years from baseline
The effect of baseline liver MR metrics (cT1 and fat) on the incidence rate of composite mild renal disease events (incident CKD, change in stage of CKD)
The impact of liver fibroinflammation (cT1 from multi-organ MRI) on other diabetes-related outcomes
Time frame: 5 years from baseline
The effect of baseline liver MR metrics (cT1 and fat) on the incidence rate of retinal intervention (photocoagulation, Vity, or use of anti-vascular endothelial growth factor injections)
The impact of liver fibroinflammation (cT1 from multi-organ MRI) on other diabetes-related outcomes
Time frame: 1 year from baseline
The effect of baseline liver MR metrics (cT1 and fat) on the incidence rate of retinal intervention (photocoagulation, Vity, or use of anti-vascular endothelial growth factor injections)
The impact of liver fibroinflammation (cT1 from multi-organ MRI) on other diabetes-related outcomes
Time frame: 3 years from baseline
The effect of baseline liver MR metrics (cT1 and fat) on the incidence rate of retinal intervention (photocoagulation, Vity, or use of anti-vascular endothelial growth factor injections)
The impact of liver fibroinflammation (cT1 from multi-organ MRI) on other diabetes-related outcomes
Time frame: 5 years from baseline
The effect of baseline liver MR metrics (cT1 and fat) on the incidence rate of lower limb amputations
The impact of liver fibroinflammation (cT1 from multi-organ MRI) on other diabetes-related outcomes
Time frame: 1 year from baseline
The effect of baseline liver MR metrics (cT1 and fat) on the incidence rate of lower limb amputations
The impact of liver fibroinflammation (cT1 from multi-organ MRI) on other diabetes-related outcomes
Time frame: 3 years from baseline
The effect of baseline liver MR metrics (cT1 and fat) on the incidence rate of lower limb amputations
The impact of liver fibroinflammation (cT1 from multi-organ MRI) on other diabetes-related outcomes
Time frame: 5 years from baseline
The effect of baseline liver MR metrics (cT1 and fat) on the incidence rate of all-cause mortality
The impact of liver fibroinflammation (cT1 from multi-organ MRI) on other diabetes-related outcomes
Time frame: 1 year from baseline
The effect of baseline liver MR metrics (cT1 and fat) on the incidence rate of all-cause mortality
The impact of liver fibroinflammation (cT1 from multi-organ MRI) on other diabetes-related outcomes
Time frame: 3 years from baseline
The effect of baseline liver MR metrics (cT1 and fat) on the incidence rate of all-cause mortality
The impact of liver fibroinflammation (cT1 from multi-organ MRI) on other diabetes-related outcomes
Time frame: 5 years from baseline
The effect of baseline liver MR metrics (cT1 and fat) on the incidence rate of CV death, liver death, renal death, cancer death, other death
The impact of liver fibroinflammation (cT1 from multi-organ MRI) on other diabetes-related outcomes
Time frame: 1 year from baseline
The effect of baseline liver MR metrics (cT1 and fat) on the incidence rate of CV death, liver death, renal death, cancer death, other death
The impact of liver fibroinflammation (cT1 from multi-organ MRI) on other diabetes-related outcomes
Time frame: 3 years from baseline
The effect of baseline liver MR metrics (cT1 and fat) on the incidence rate of CV death, liver death, renal death, cancer death, other death
The impact of liver fibroinflammation (cT1 from multi-organ MRI) on other diabetes-related outcomes
Time frame: 5 years from baseline
The effect of baseline liver MR metrics (cT1 and fat) on the incidence rate of liver events (decompensation, hepatocellular carcinoma diagnosis, transplant, portal hypertension)
The impact of liver fibroinflammation (cT1 from multi-organ MRI) on other diabetes-related outcomes
Time frame: 1 year from baseline
The effect of baseline liver MR metrics (cT1 and fat) on the incidence rate of liver events (decompensation, hepatocellular carcinoma diagnosis, transplant, portal hypertension)
The impact of liver fibroinflammation (cT1 from multi-organ MRI) on other diabetes-related outcomes
Time frame: 3 years from baseline
The effect of baseline liver MR metrics (cT1 and fat) on the incidence rate of liver events (decompensation, hepatocellular carcinoma diagnosis, transplant, portal hypertension)
The impact of liver fibroinflammation (cT1 from multi-organ MRI) on other diabetes-related outcomes
Time frame: 5 years from baseline
The effect of baseline liver MR metrics (cT1 and fat) on the incidence rate of non-hepatic cancer
The impact of liver fibroinflammation (cT1 from multi-organ MRI) on other diabetes-related outcomes
Time frame: 1 year from baseline
The effect of baseline liver MR metrics (cT1 and fat) on the incidence rate of non-hepatic cancer
The impact of liver fibroinflammation (cT1 from multi-organ MRI) on other diabetes-related outcomes
Time frame: 3 years from baseline
The effect of baseline liver MR metrics (cT1 and fat) on the incidence rate of non-hepatic cancer
The impact of liver fibroinflammation (cT1 from multi-organ MRI) on other diabetes-related outcomes
Time frame: 5 years from baseline
Potential effect of body composition, liver volume, and aortic (distensibility, diameter) MRI metrics increase and incidence of 5-point MACE (CV death, non-fatal stroke, myocardial infarction, heart failure, hospitalisation for CV causes
The impact that liver volume, whole body composition and, abnormalities in the aorta have on diabetes-related clinical outcomes using multiparametric MRI
Time frame: 1 year from baseline
Potential effect of body composition, liver volume, and aortic (distensibility, diameter) MRI metrics increase with incidence of 5-point MACE (CV death, non-fatal stroke, myocardial infarction, heart failure, hospitalisation for CV causes
The impact that liver volume, whole body composition and, abnormalities in the aorta have on diabetes-related clinical outcomes using multiparametric MRI
Time frame: 3 years from baseline
Potential effect of body composition, liver volume, and aortic (distensibility, diameter) MRI metrics increase with incidence of 5-point MACE (CV death, non-fatal stroke, myocardial infarction, heart failure, hospitalisation for CV causes
The impact that liver volume, whole body composition and, abnormalities in the aorta have on diabetes-related clinical outcomes using multiparametric MRI
Time frame: 5 years from baseline
Potential effect of body composition, liver volume, and aortic (distensibility, diameter) MRI metrics increase and incidence of composite severe renal disease events (renal replacement therapy, renal death)
The impact that liver volume, whole body composition and, abnormalities in the aorta have on diabetes-related clinical outcomes using multiparametric MRI
Time frame: 1 year from baseline
Potential effect of body composition, liver volume, and aortic (distensibility, diameter) MRI metrics increase and incidence of composite severe renal disease events (renal replacement therapy, renal death)
The impact that liver volume, whole body composition and, abnormalities in the aorta have on diabetes-related clinical outcomes using multiparametric MRI
Time frame: 3 years from baseline
Potential effect of body composition, liver volume, and aortic (distensibility, diameter) MRI metrics increase and incidence of composite severe renal disease events (renal replacement therapy, renal death)
The impact that liver volume, whole body composition and, abnormalities in the aorta have on diabetes-related clinical outcomes using multiparametric MRI
Time frame: 5 years from baseline
Potential effect of body composition, liver volume, and aortic (distensibility, diameter) MRI metrics increase and incidence of composite mild renal disease events (incident CKD, change in stage of CKD)
The impact that liver volume, whole body composition and, abnormalities in the aorta have on diabetes-related clinical outcomes using multiparametric MRI
Time frame: 1 year from baseline
Potential effect of body composition, liver volume, and aortic (distensibility, diameter) MRI metrics increase and incidence of composite mild renal disease events (incident CKD, change in stage of CKD)
The impact that liver volume, whole body composition and, abnormalities in the aorta have on diabetes-related clinical outcomes using multiparametric MRI
Time frame: 3 years from baseline
Potential effect of body composition, liver volume, and aortic (distensibility, diameter) MRI metrics increase and incidence of composite mild renal disease events (incident CKD, change in stage of CKD)
The impact that liver volume, whole body composition and, abnormalities in the aorta have on diabetes-related clinical outcomes using multiparametric MRI
Time frame: 5 years from baseline
Potential effect of body composition, liver volume, and aortic (distensibility, diameter) MRI metrics increase and incidence of retinal intervention (photocoagulation, Vity, or use of anti-vascular endothelial growth factor injections)
The impact that liver volume, whole body composition and, abnormalities in the aorta have on diabetes-related clinical outcomes using multiparametric MRI
Time frame: 1 year from baseline
Potential effect of body composition, liver volume, and aortic (distensibility, diameter) MRI metrics increase and incidence of retinal intervention (photocoagulation, Vity, or use of anti-vascular endothelial growth factor injections)
The impact that liver volume, whole body composition and, abnormalities in the aorta have on diabetes-related clinical outcomes using multiparametric MRI
Time frame: 3 years from baseline
Potential effect of body composition, liver volume, and aortic (distensibility, diameter) MRI metrics increase and incidence of retinal intervention (photocoagulation, Vity, or use of anti-vascular endothelial growth factor injections)
The impact that liver volume, whole body composition and, abnormalities in the aorta have on diabetes-related clinical outcomes using multiparametric MRI
Time frame: 5 years from baseline
Potential effect of body composition, liver volume, and aortic (distensibility, diameter) MRI metrics increase and incidence of lower limb amputations
The impact that liver volume, whole body composition and, abnormalities in the aorta have on diabetes-related clinical outcomes using multiparametric MRI
Time frame: 1 year from baseline
Potential effect of body composition, liver volume, and aortic (distensibility, diameter) MRI metrics increase and incidence of lower limb amputations
The impact that liver volume, whole body composition and, abnormalities in the aorta have on diabetes-related clinical outcomes using multiparametric MRI
Time frame: 3 years from baseline
Potential effect of body composition, liver volume, and aortic (distensibility, diameter) MRI metrics increase and incidence of lower limb amputations
The impact that liver volume, whole body composition and, abnormalities in the aorta have on diabetes-related clinical outcomes using multiparametric MRI
Time frame: 5 years from baseline
Potential effect of body composition, liver volume, and aortic (distensibility, diameter) MRI metrics increase and incidence of all-cause mortality
The impact that liver volume, whole body composition and, abnormalities in the aorta have on diabetes-related clinical outcomes using multiparametric MRI
Time frame: 1 year from baseline
Potential effect of body composition, liver volume, and aortic (distensibility, diameter) MRI metrics increase and incidence of all-cause mortality
The impact that liver volume, whole body composition and, abnormalities in the aorta have on diabetes-related clinical outcomes using multiparametric MRI
Time frame: 3 years from baseline
Potential effect of body composition, liver volume, and aortic (distensibility, diameter) MRI metrics increase and incidence of all-cause mortality
The impact that liver volume, whole body composition and, abnormalities in the aorta have on diabetes-related clinical outcomes using multiparametric MRI
Time frame: 5 years from baseline
Potential effect of body composition, liver volume, and aortic (distensibility, diameter) MRI metrics increase and incidence of CV death, liver death, renal death, cancer death, other death
The impact that liver volume, whole body composition and, abnormalities in the aorta have on diabetes-related clinical outcomes using multiparametric MRI
Time frame: 1 year from baseline
Potential effect of body composition, liver volume, and aortic (distensibility, diameter) MRI metrics increase and incidence of CV death, liver death, renal death, cancer death, other death
The impact that liver volume, whole body composition and, abnormalities in the aorta have on diabetes-related clinical outcomes using multiparametric MRI
Time frame: 3 years from baseline
Potential effect of body composition, liver volume, and aortic (distensibility, diameter) MRI metrics increase and incidence of CV death, liver death, renal death, cancer death, other death
The impact that liver volume, whole body composition and, abnormalities in the aorta have on diabetes-related clinical outcomes using multiparametric MRI
Time frame: 5 years from baseline
Potential effect of body composition, liver volume, and aortic (distensibility, diameter) MRI metrics increase and incidence of liver events (decompensation, hepatocellular carcinoma diagnosis, transplant, portal hypertension)
The impact that liver volume, whole body composition and, abnormalities in the aorta have on diabetes-related clinical outcomes using multiparametric MRI
Time frame: 1 year from baseline
Potential effect of body composition, liver volume, and aortic (distensibility, diameter) MRI metrics increase and incidence of liver events (decompensation, hepatocellular carcinoma diagnosis, transplant, portal hypertension)
The impact that liver volume, whole body composition and, abnormalities in the aorta have on diabetes-related clinical outcomes using multiparametric MRI
Time frame: 3 years from baseline
Potential effect of body composition, liver volume, and aortic (distensibility, diameter) MRI metrics increase and incidence of liver events (decompensation, hepatocellular carcinoma diagnosis, transplant, portal hypertension)
The impact that liver volume, whole body composition and, abnormalities in the aorta have on diabetes-related clinical outcomes using multiparametric MRI
Time frame: 5 years from baseline
Potential effect of body composition, liver volume, and aortic (distensibility, diameter) MRI metrics increase and incidence of non-hepatic cancer
The impact that liver volume, whole body composition and, abnormalities in the aorta have on diabetes-related clinical outcomes using multiparametric MRI
Time frame: 1 year from baseline
Potential effect of body composition, liver volume, and aortic (distensibility, diameter) MRI metrics increase and incidence of non-hepatic cancer
The impact that liver volume, whole body composition and, abnormalities in the aorta have on diabetes-related clinical outcomes using multiparametric MRI
Time frame: 3 years from baseline
Potential effect of body composition, liver volume, and aortic (distensibility, diameter) MRI metrics increase and incidence of non-hepatic cancer
The impact that liver volume, whole body composition and, abnormalities in the aorta have on diabetes-related clinical outcomes using multiparametric MRI
Time frame: 5 years from baseline
The effect of retinopathy severity (no DR, mild NPDR, moderate NPDR, severe NPDR, PDR, advanced PDR) on the incidence rate of 5-point MACE (CV death, non-fatal stroke, myocardial infarction, heart failure, hospitalisation for CV causes)
The impact of the severity of diabetic retinopathy on cardiovascular and other diabetes-related outcomes
Time frame: 1 year from baseline
The effect of retinopathy severity (no DR, mild NPDR, moderate NPDR, severe NPDR, PDR, advanced PDR) on the incidence rate of 5-point MACE (CV death, non-fatal stroke, myocardial infarction, heart failure, hospitalisation for CV causes)
The impact of the severity of diabetic retinopathy on cardiovascular and other diabetes-related outcomes
Time frame: 3 years from baseline
The effect of retinopathy severity (no DR, mild NPDR, moderate NPDR, severe NPDR, PDR, advanced PDR) on the incidence rate of 5-point MACE (CV death, non-fatal stroke, myocardial infarction, heart failure, hospitalisation for CV causes)
The impact of the severity of diabetic retinopathy on cardiovascular and other diabetes-related outcomes
Time frame: 5 years from baseline
The effect of retinopathy severity (no DR, mild NPDR, moderate NPDR, severe NPDR, PDR, advanced PDR) on the incidence rate of the composite severe renal disease events (renal replacement therapy, renal death)
The impact of the severity of diabetic retinopathy on cardiovascular and other diabetes-related outcomes
Time frame: 1 year from baseline
The effect of retinopathy severity (no DR, mild NPDR, moderate NPDR, severe NPDR, PDR, advanced PDR) on the incidence rate of the composite severe renal disease events (renal replacement therapy, renal death)
The impact of the severity of diabetic retinopathy on cardiovascular and other diabetes-related outcomes
Time frame: 3 years from baseline
The effect of retinopathy severity (no DR, mild NPDR, moderate NPDR, severe NPDR, PDR, advanced PDR) on the incidence rate of the composite severe renal disease events (renal replacement therapy, renal death)
The impact of the severity of diabetic retinopathy on cardiovascular and other diabetes-related outcomes
Time frame: 5 years from baseline
The effect of retinopathy severity (no DR, mild NPDR, moderate NPDR, severe NPDR, PDR, advanced PDR) on the incidence rate of the composite mild renal disease events (incident CKD, change in stage of CKD)
The impact of the severity of diabetic retinopathy on cardiovascular and other diabetes-related outcomes
Time frame: 1 year from baseline
The effect of retinopathy severity (no DR, mild NPDR, moderate NPDR, severe NPDR, PDR, advanced PDR) on the incidence rate of the composite mild renal disease events (incident CKD, change in stage of CKD)
The impact of the severity of diabetic retinopathy on cardiovascular and other diabetes-related outcomes
Time frame: 3 years from baseline
The effect of retinopathy severity (no DR, mild NPDR, moderate NPDR, severe NPDR, PDR, advanced PDR) on the incidence rate of the composite mild renal disease events (incident CKD, change in stage of CKD)
The impact of the severity of diabetic retinopathy on cardiovascular and other diabetes-related outcomes
Time frame: 5 years from baseline
The effect of retinopathy severity (no DR, mild NPDR, moderate NPDR, severe NPDR, PDR, advanced PDR) on the incidence rate of the retinal intervention (photocoagulation, Vity, or use of anti-vascular endothelial growth factor injections)
The impact of the severity of diabetic retinopathy on cardiovascular and other diabetes-related outcomes
Time frame: 1 year from baseline
The effect of retinopathy severity (no DR, mild NPDR, moderate NPDR, severe NPDR, PDR, advanced PDR) on the incidence rate of the retinal intervention (photocoagulation, Vity, or use of anti-vascular endothelial growth factor injections)
The impact of the severity of diabetic retinopathy on cardiovascular and other diabetes-related outcomes
Time frame: 3 years from baseline
The effect of retinopathy severity (no DR, mild NPDR, moderate NPDR, severe NPDR, PDR, advanced PDR) on the incidence rate of the retinal intervention (photocoagulation, Vity, or use of anti-vascular endothelial growth factor injections)
The impact of the severity of diabetic retinopathy on cardiovascular and other diabetes-related outcomes
Time frame: 5 years from baseline
The effect of retinopathy severity (no DR, mild NPDR, moderate NPDR, severe NPDR, PDR, advanced PDR) on the incidence rate of lower limb amputations
The impact of the severity of diabetic retinopathy on cardiovascular and other diabetes-related outcomes
Time frame: 1 year from baseline
The effect of retinopathy severity (no DR, mild NPDR, moderate NPDR, severe NPDR, PDR, advanced PDR) on the incidence rate of lower limb amputations
The impact of the severity of diabetic retinopathy on cardiovascular and other diabetes-related outcomes
Time frame: 3 years from baseline
The effect of retinopathy severity (no DR, mild NPDR, moderate NPDR, severe NPDR, PDR, advanced PDR) on the incidence rate of lower limb amputations
The impact of the severity of diabetic retinopathy on cardiovascular and other diabetes-related outcomes
Time frame: 5 years from baseline
The effect of retinopathy severity (no DR, mild NPDR, moderate NPDR, severe NPDR, PDR, advanced PDR) on the incidence rate of all-cause mortality
The impact of the severity of diabetic retinopathy on cardiovascular and other diabetes-related outcomes
Time frame: 1 year from baseline
The effect of retinopathy severity (no DR, mild NPDR, moderate NPDR, severe NPDR, PDR, advanced PDR) on the incidence rate of all-cause mortality
The impact of the severity of diabetic retinopathy on cardiovascular and other diabetes-related outcomes
Time frame: 3 years from baseline
The effect of retinopathy severity (no DR, mild NPDR, moderate NPDR, severe NPDR, PDR, advanced PDR) on the incidence rate of all-cause mortality
The impact of the severity of diabetic retinopathy on cardiovascular and other diabetes-related outcomes
Time frame: 5 years from baseline
The effect of retinopathy severity (no DR, mild NPDR, moderate NPDR, severe NPDR, PDR, advanced PDR) on the incidence rate of CV death, liver death, renal death, cancer death, other death
The impact of the severity of diabetic retinopathy on cardiovascular and other diabetes-related outcomes
Time frame: 1 year from baseline
The effect of retinopathy severity (no DR, mild NPDR, moderate NPDR, severe NPDR, PDR, advanced PDR) on the incidence rate of CV death, liver death, renal death, cancer death, other death
The impact of the severity of diabetic retinopathy on cardiovascular and other diabetes-related outcomes
Time frame: 3 years from baseline
The effect of retinopathy severity (no DR, mild NPDR, moderate NPDR, severe NPDR, PDR, advanced PDR) on the incidence rate of CV death, liver death, renal death, cancer death, other death
The impact of the severity of diabetic retinopathy on cardiovascular and other diabetes-related outcomes
Time frame: 5 years from baseline
The effect of retinopathy severity (no DR, mild NPDR, moderate NPDR, severe NPDR, PDR, advanced PDR) on the incidence rate of liver events (decompensation, hepatocellular carcinoma diagnosis, transplant, portal hypertension
The impact of the severity of diabetic retinopathy on cardiovascular and other diabetes-related outcomes
Time frame: 1 year from baseline
The effect of retinopathy severity (no DR, mild NPDR, moderate NPDR, severe NPDR, PDR, advanced PDR) on the incidence rate of liver events (decompensation, hepatocellular carcinoma diagnosis, transplant, portal hypertension
The impact of the severity of diabetic retinopathy on cardiovascular and other diabetes-related outcomes
Time frame: 3 years from baseline
The effect of retinopathy severity (no DR, mild NPDR, moderate NPDR, severe NPDR, PDR, advanced PDR) on the incidence rate of liver events (decompensation, hepatocellular carcinoma diagnosis, transplant, portal hypertension
The impact of the severity of diabetic retinopathy on cardiovascular and other diabetes-related outcomes
Time frame: 5 years from baseline
The effect of retinopathy severity (no DR, mild NPDR, moderate NPDR, severe NPDR, PDR, advanced PDR) on the incidence rate of non-hepatic cancer
The impact of the severity of diabetic retinopathy on cardiovascular and other diabetes-related outcomes
Time frame: 1 year from baseline
The effect of retinopathy severity (no DR, mild NPDR, moderate NPDR, severe NPDR, PDR, advanced PDR) on the incidence rate of non-hepatic cancer
The impact of the severity of diabetic retinopathy on cardiovascular and other diabetes-related outcomes
Time frame: 3 years from baseline
The effect of retinopathy severity (no DR, mild NPDR, moderate NPDR, severe NPDR, PDR, advanced PDR) on the incidence rate of non-hepatic cancer
The impact of the severity of diabetic retinopathy on cardiovascular and other diabetes-related outcomes
Time frame: 5 years from baseline
The effect of age of T2DM diagnosis (early onset and under 45 year of age, usual onset) on the incidence rate of 5-point MACE (CV death, non-fatal stroke, myocardial infarction, heart failure, hospitalisation for CV causes)
The impact of age of onset of T2DM on cardiovascular and other diabetes-related outcomes
Time frame: 1 year from baseline
The effect of age of T2DM diagnosis (early onset and under 45 year of age, usual onset) on the incidence rate of 5-point MACE (CV death, non-fatal stroke, myocardial infarction, heart failure, hospitalisation for CV causes)
The impact of age of onset of T2DM on cardiovascular and other diabetes-related outcomes
Time frame: 3 years from baseline
The effect of age of T2DM diagnosis (early onset and under 45 year of age, usual onset) on the incidence rate of 5-point MACE (CV death, non-fatal stroke, myocardial infarction, heart failure, hospitalisation for CV causes)
The impact of age of onset of T2DM on cardiovascular and other diabetes-related outcomes
Time frame: 5 years from baseline
The effect of age of T2DM diagnosis (early onset and under 45 year of age, usual onset) on the incidence rate of composite severe renal disease events (renal replacement therapy, renal death)
The impact of age of onset of T2DM on cardiovascular and other diabetes-related outcomes
Time frame: 1 year from baseline
The effect of age of T2DM diagnosis (early onset and under 45 year of age, usual onset) on the incidence rate of composite severe renal disease events (renal replacement therapy, renal death)
The impact of age of onset of T2DM on cardiovascular and other diabetes-related outcomes
Time frame: 3 years from baseline
The effect of age of T2DM diagnosis (early onset and under 45 year of age, usual onset) on the incidence rate of composite severe renal disease events (renal replacement therapy, renal death)
The impact of age of onset of T2DM on cardiovascular and other diabetes-related outcomes
Time frame: 5 years from baseline
The effect of age of T2DM diagnosis (early onset and under 45 year of age, usual onset) on the incidence rate of composite mild renal disease events (incident CKD, change in stage of CKD)
The impact of age of onset of T2DM on cardiovascular and other diabetes-related outcomes
Time frame: 1 year from baseline
The effect of age of T2DM diagnosis (early onset and under 45 year of age, usual onset) on the incidence rate of composite mild renal disease events (incident CKD, change in stage of CKD)
The impact of age of onset of T2DM on cardiovascular and other diabetes-related outcomes
Time frame: 3 years from baseline
The effect of age of T2DM diagnosis (early onset and under 45 year of age, usual onset) on the incidence rate of composite mild renal disease events (incident CKD, change in stage of CKD)
The impact of age of onset of T2DM on cardiovascular and other diabetes-related outcomes
Time frame: 5 years from baseline
The effect of age of T2DM diagnosis (early onset and under 45 year of age, usual onset) on the incidence rate of retinal intervention (photocoagulation, Vity, or use of anti-vascular endothelial growth factor injections)
The impact of age of onset of T2DM on cardiovascular and other diabetes-related outcomes
Time frame: 1 year from baseline
The effect of age of T2DM diagnosis (early onset and under 45 year of age, usual onset) on the incidence rate of retinal intervention (photocoagulation, Vity, or use of anti-vascular endothelial growth factor injections)
The impact of age of onset of T2DM on cardiovascular and other diabetes-related outcomes
Time frame: 3 years from baseline
The effect of age of T2DM diagnosis (early onset and under 45 year of age, usual onset) on the incidence rate of retinal intervention (photocoagulation, Vity, or use of anti-vascular endothelial growth factor injections)
The impact of age of onset of T2DM on cardiovascular and other diabetes-related outcomes
Time frame: 5 years from baseline
The effect of age of T2DM diagnosis (early onset and under 45 year of age, usual onset) on the incidence rate of lower limb amputations
The impact of age of onset of T2DM on cardiovascular and other diabetes-related outcomes
Time frame: 1 year from baseline
The effect of age of T2DM diagnosis (early onset and under 45 year of age, usual onset) on the incidence rate of lower limb amputations
The impact of age of onset of T2DM on cardiovascular and other diabetes-related outcomes
Time frame: 3 years from baseline
The effect of age of T2DM diagnosis (early onset and under 45 year of age, usual onset) on the incidence rate of lower limb amputations
The impact of age of onset of T2DM on cardiovascular and other diabetes-related outcomes
Time frame: 5 years from baseline
The effect of age of T2DM diagnosis (early onset and under 45 year of age, usual onset) on the incidence rate of all-cause mortality
The impact of age of onset of T2DM on cardiovascular and other diabetes-related outcomes
Time frame: 1 year from baseline
The effect of age of T2DM diagnosis (early onset and under 45 year of age, usual onset) on the incidence rate of all-cause mortality
The impact of age of onset of T2DM on cardiovascular and other diabetes-related outcomes
Time frame: 3 years from baseline
The effect of age of T2DM diagnosis (early onset and under 45 year of age, usual onset) on the incidence rate of all-cause mortality
The impact of age of onset of T2DM on cardiovascular and other diabetes-related outcomes
Time frame: 5 years from baseline
The effect of age of T2DM diagnosis (early onset and under 45 year of age, usual onset) on the incidence rate of CV death, liver death, renal death, cancer death, other death
The impact of age of onset of T2DM on cardiovascular and other diabetes-related outcomes
Time frame: 1 year from baseline
The effect of age of T2DM diagnosis (early onset and under 45 year of age, usual onset) on the incidence rate of CV death, liver death, renal death, cancer death, other death
The impact of age of onset of T2DM on cardiovascular and other diabetes-related outcomes
Time frame: 3 years from baseline
The effect of age of T2DM diagnosis (early onset and under 45 year of age, usual onset) on the incidence rate of CV death, liver death, renal death, cancer death, other death
The impact of age of onset of T2DM on cardiovascular and other diabetes-related outcomes
Time frame: 5 years from baseline
The effect of age of T2DM diagnosis (early onset and under 45 year of age, usual onset) on the incidence rate of liver events (decompensation, hepatocellular carcinoma diagnosis, transplant, portal hypertension
The impact of age of onset of T2DM on cardiovascular and other diabetes-related outcomes
Time frame: 1 year from baseline
The effect of age of T2DM diagnosis (early onset and under 45 year of age, usual onset) on the incidence rate of liver events (decompensation, hepatocellular carcinoma diagnosis, transplant, portal hypertension
The impact of age of onset of T2DM on cardiovascular and other diabetes-related outcomes
Time frame: 3 years from baseline
The effect of age of T2DM diagnosis (early onset and under 45 year of age, usual onset) on the incidence rate of liver events (decompensation, hepatocellular carcinoma diagnosis, transplant, portal hypertension
The impact of age of onset of T2DM on cardiovascular and other diabetes-related outcomes
Time frame: 5 years from baseline
The effect of age of T2DM diagnosis (early onset and under 45 year of age, usual onset) on the incidence rate of non-hepatic cancer
The impact of age of onset of T2DM on cardiovascular and other diabetes-related outcomes
Time frame: 1 year from baseline
The effect of age of T2DM diagnosis (early onset and under 45 year of age, usual onset) on the incidence rate of non-hepatic cancer
The impact of age of onset of T2DM on cardiovascular and other diabetes-related outcomes
Time frame: 3 years from baseline
The effect of age of T2DM diagnosis (early onset and under 45 year of age, usual onset) on the incidence rate of non-hepatic cancer
The impact of age of onset of T2DM on cardiovascular and other diabetes-related outcomes
Time frame: 5 years from baseline
Prevalence of patients with evidence of metabolic dysfunction-associated steatotic liver disease in patients with diabetic retinopathy of different severity (no DR, mild NPDR, moderate NPDR, severe NPDR, PDR, advanced PDR)
The co-prevalence of diabetic retinopathy (DR) and metabolic dysfunction-associated steatotic liver disease (MASLD), using multi-parametric abdominal MRI
Time frame: 1 year from baseline
Correlations between liver MRI metrics (organ volume, fat infiltration and fibroinflammation) and eye metrics (retinal layer thickness by OCT, discrete retinopathy scores)
The correlation between severity of eye disease and MRI-derived metrics of liver disease using multiparametric MRI
Time frame: 1 year from baseline
Plan to share: No
No publications or documents are linked to this record.
Started May 2022 (actual). Primary completion is estimated for Jun 2034, 145 months after the start.
Of 170 industry-sponsored observational studies under Diabetes Mellitus, Type 2, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 44. This study's planned 145 months is above that.
Counting every sponsor, half of 602 studies reached it within 32 months; a quarter within 17 and three quarters within 62.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.